83 results on '"Kesselheim, Aaron S."'
Search Results
2. Will Medicare Price Negotiation Delay Cancer-Drug Launches?
3. Federal Oversight of Laboratory-Developed Tests.
4. The History of Health Law in the United States.
5. Improving the Use of FDA Advisory Committees.
6. Promoting Pediatric Drug Research and Labeling - Outcomes of Legislation.
7. Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval.
8. Specialty Drugs - A Distinctly American Phenomenon.
9. The U.S. Insulin Crisis - Rationing a Lifesaving Medication Discovered in the 1920s.
10. Fundamentals of Health Law - A New Perspective Series.
11. Accelerated Approval and Expensive Drugs - A Challenging Combination.
12. Reforming the Orphan Drug Act for the 21st Century.
13. Pharmaceutical Protections in U.S. Trade Deals - What Do Americans Get in Return?
14. Massachusetts' Proposed Medicaid Reforms - Cheaper Drugs and Better Coverage?
15. Regulating Off-Label Promotion - A Critical Test.
16. Ensuring Patient Privacy in Data Sharing for Postapproval Research.
17. Gene Patenting -- The Supreme Court Finally Speaks.
18. Distributions of Industry Payments to Massachusetts Physicians.
19. Eroding Judicial Deference to the FDA -- Consequences for Public Health.
20. A Randomized Study of How Physicians Interpret Research Funding Disclosures.
21. “Pay for Delay” Settlements of Disputes over Pharmaceutical Patents.
22. Why Do the Same Drugs Look Different? Pills, Trade Dress, and Public Health.
23. Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation.
24. Gene Patenting — Is the Pendulum Swinging Back?
25. Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies.
26. Regulating Homeopathic Products - A Century of Dilute Interest.
27. The Supreme Court, Process Patents, and Medical Innovation.
28. Pharmaceutical Promotion to Physicians and First Amendment Rights.
29. Scientific and Legal Viability of Follow-on Protein Drugs.
30. Sources of Innovation in Gene Therapies -- Approaches to Achieving Affordable Prices.
31. The 21st Century Cures Act -- Will It Take Us Back in Time?
32. The Medical Device Excise Tax -- Over before It Begins?
33. Risk, Responsibility, and Generic Drugs.
34. User Fees and Beyond — The FDA Safety and Innovation Act of 2012.
35. Biomarkers Unbound — The Supreme Court's Ruling on Diagnostic-Test Patents.
36. Who Owns Federally Funded Research? The Supreme Court and the Bayh–Dole Act.
37. Residents: Workers or Students in the Eyes of the Law?
38. Pharmaceutical Marketing and the New Social Media.
39. Incentives for Drug Development — The Curious Case of Colchicine.
40. Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics.
41. The Supreme Court, Preemption, and Malpractice Liability.
42. Drug Development for Neglected Diseases — The Trouble with FDA Review Vouchers.
43. A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights.
44. The 21st Century Cures Act.
45. The Watchman Saga -- Closure at Last?
46. Prescription-Drug Coupons -- No Such Thing as a Free Lunch.
47. The medical device excise tax--over before it begins?
48. Incentives for Drug Development — The Curious Case of Colchicine.
49. Market Exclusivity for Biologics.
50. Preemption and Malpractice Liability.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.